8:00 Registration
8:30 Opening Address - André Capron, Academician of Medecine
9:00 Alain Huriez, Chief Executive Officer TcLand Expression

SESSION 1 – RARE DISEASES



_ CHAIRMAN : Daniel Scherman

9:15 Thomas Voit, the Myology Institute, France

Biomarkers in Duchenne Muscular Dystrophy : defining what is known and exploring the unknown

9:45 Marc Peschanski, Director of Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (I-STEM), France

Pluripotent stem cells as a tool for drug discovery in monogenic diseases

10:15 Brenda Wong, Child neurology, Cincinnati Children’s Hospital Medical Center, USA

Gene expression profiling (transcriptomics) of blood in Duchenne Muscular Dystrophy

10:45 Coffee break

SESSION 2 – POLYFACTORIAL DISEASES



_ CHAIRMAN : Guillaume Charpentier

11:15 Nabila Bouatia-Naji, Institut Pasteur de Lille, France

From Genomics to new biomarkers for diabetes and obesity

11:45 Pierre Miossec, Centre de Rhumatologie, CHU Lyon, France

Markers of disease heterogeneity and response to treatment in rheumatoid arthritis

SESSION 3 – NEGLECTED DISEASES



_ CHAIRMAN : Yves Champey

 12:15 Piero Olliaro, World Health Organization, Switzerland

Challenges with biomarkers for neglected tropical diseases

12:45 Robert S. Wallis, Pfizer Global Research & Development

Biomarkers for tuberculosis

13:15 Cocktail lunch

SESSION 4 – NEW TECHNICAL TOOLS



_ CHAIRMAN : Jérôme Garin

14:30 Bruno Domon, Institute of Molecular Systems Biology, ETH Zurich

Novel mass spectrometry-based approaches applied to biomarker discovery and evaluation

15:00 David Cumming, University of Glasgow, UK

Integrated Sensors

15:30 Michel Werner, CEA

The hight throughput sequencing revolution in functional genomics : Application to the study of transcription

SESSION 5 – STATISTICS, BIO-INFORMATICS



_ CHAIRMAN : Laurent Becquemont

16:00 Alessandra Cervino, Vice-president Biostatistics & Bioinformatics TCLand Expression

A data integrated approach to biomarker discovery

16:30 Alessandro Quattrone, Center for integrative biology, Trento, Italy

Why biomarker identification by transcriptome analysis is so difficult

17:00 Coffee break

SESSION 6 – HEALTH POLICY



_ CHAIRMAN : Didier Caizergues

17:30 Isabelle Durand-Zaleski, Henri Mondor Hospital, France

The use of biomarkers for priority setting and allocation of healthcare resources

18:00 Jean-Claude Ghislain, AFSSAPS, France

Current regulatory framework of in vitro diagnostic medical devices, perspectives and accompanying innovation

18:30 Closing address – Pierre Tambourin, CEO Genopole